Skip to main content

Advertisement

SpringerLink
Log in

The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Hyperuricemia and metabolic acidosis have emerged as important risk factors for progression of kidney disease. In this study, we aimed to investigate the effects of allopurinol on metabolic acidosis and endothelial functions in hyperuricemic stage 2–4 chronic kidney disease (CKD) patients.

Methods

Thirty patients with stage 2–4 CKD and serum uric acid levels over 5.5 mg/dl were included in the study group. They were prescribed 300 mg/day per oral allopurinol treatment for three months. Age- and gender-matched CKD patients (n = 30) with similar clinical characteristics were taken as the control group and were not given allopurinol treatment. Endothelial functions were measured via flow-mediated dilatation (∆FMD %) over the forearm. pH and HCO3 levels in venous blood, Cr clearance and proteinuria levels were calculated in all patients at baseline and in the third month.

Results

Serum uric acid levels significantly decreased in the study group from 7.9 ± 1.6 to 6.4 ± 1.7 (p < 0.001). Cr clearance (from 43.4 ± 20.1 to 51.4 ± 24.9, p = 0.011), serum bicarbonate levels (from 21.4 ± 3.4 to 23.0 ± 3.4, p = 0.007) and ΔFMD % values (from 5.8 ± 2.5 to 6.2 ± 2.7, p = 0.006) increased significantly in the allopurinol group. There were no significant changes except for ∆FMD % values (decreased from 6.27 ± 1.62 to 5.71 ± 1.90, p = 0.005) in the control group. ∆FMD % variations within the two groups were clearly significant in the repeated ANOVA general linear model.

Conclusion

We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Clev Clin J Med. 2008;75:13–6.

    Article  Google Scholar 

  3. Saito T, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Metabolic syndrome and risk of progression of chronic kidney disease: a single-center cohort study in Japan. Heart Vessels. 2013;28:323–9.

    Article  PubMed  Google Scholar 

  4. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.

    Article  PubMed  Google Scholar 

  5. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239–47.

    Article  CAS  PubMed  Google Scholar 

  6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol. 2011;33:298–304.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:1–7.

    Article  Google Scholar 

  9. Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessels. 2013. doi:10.1007/s00380-013-0396-0.

    PubMed  Google Scholar 

  10. Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23:280–6.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227–33.

    Article  CAS  PubMed  Google Scholar 

  12. Ruggiero C, Cherubini A, Ble A, Bos AJ, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur J Heart. 2006;27:1174–81.

    Article  CAS  Google Scholar 

  13. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.

    Article  PubMed  Google Scholar 

  14. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.

    Article  CAS  PubMed  Google Scholar 

  15. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14:164.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sincer I, Kurtoglu E, Calıskan M, Akkaya E, Vuruskan E, Küçükosmanoglu M, et al. Significant correlation between uric acid levels and flow-mediated dilatation in patients with masked hypertension. Clin Exp Hypertens. 20 Feb 2014 [Epub ahead of print]. doi:10.3109/10641963.2013.827694.

  17. Williams B, Hattersley J, Layward E, Walls J. Metabolic acidosis and skeletal muscle adaptation to low-protein diets in chronic uremia. Kidney Int. 1991;40:779–86.

    Article  CAS  PubMed  Google Scholar 

  18. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20:2075–84.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in individuals with low GFR reduces kidney endothelin production, reduces kidney injury, and better preserves GFR. Kidney Int. 2010;77:617–23.

    Article  CAS  PubMed  Google Scholar 

  20. Gao H, Lew SQ, Bosch JP. Moderate metabolic acidosis and its effects on serum parameters in hemodialysis patients. Nephron. 2000;86:135–8.

    Article  CAS  PubMed  Google Scholar 

  21. Moviat M, Terpstra AM, Ruitenbeek W, Kluijtmans LA, Pickkers P, van der Hoeven JG. Contribution of various metabolites to the unmeasured anions in critically ill patients with metabolic acidosis. Crit Care Med. 2008;36:752–8.

    Article  CAS  PubMed  Google Scholar 

  22. Forni LG, McKinnon W, Lord GA, Treacher DF, Peron JM, Hilton PJ. Circulating anions usually associated with the Krebs cycle in patients with metabolic acidosis. Crit Care. 2005;9:R591–5.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Paisansinsup T, Breitenstein MK, Schousboe JT. Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol. J Clin Rheumatol. 2013;19:180–6.

    Article  PubMed  Google Scholar 

  25. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We have no financial disclosures to declare and no conflicts of interest to report.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Isparta, Turkey

    Dilara Bayram

  2. Division of Nephrology, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Cunur, 32200, Isparta, Turkey

    M. Tuğrul Sezer, Salih İnal, Atila Altuntaş & Veysel Kıdır

  3. Department of Biostatistics and Medical Informatics, Süleyman Demirel University Faculty of Medicine, Isparta, Turkey

    Hikmet Orhan

Authors
  1. Dilara Bayram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Tuğrul Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salih İnal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atila Altuntaş
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Veysel Kıdır
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hikmet Orhan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salih İnal.

Additional information

Trial registration number: ACTRN12614000320651, Australian New Zealand Clinical Trials Registry (ANZCTR).

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bayram, D., Tuğrul Sezer, M., İnal, S. et al. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol 19, 443–449 (2015). https://doi.org/10.1007/s10157-014-1012-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-014-1012-z

Keywords

Search

Navigation